Stock Analysis on Net

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

Statement of Comprehensive Income

Regeneron Pharmaceuticals Inc., consolidated statement of comprehensive income

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Net income 3,953,600 4,338,400 8,075,300 3,513,200 2,115,800
Unrealized gain (loss) on debt securities 158,200 (213,600) (56,400) 9,100 35,900
Gain (loss) on foreign currency translation (300)
Unrealized gain (loss) on cash flow hedges 1,000 900 (900) (2,500)
Other comprehensive income (loss), net of tax 157,900 (212,600) (55,500) 8,200 33,400
Comprehensive income 4,111,500 4,125,800 8,019,800 3,521,400 2,149,200

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Comprehensive income item Description The company
Net income The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Regeneron Pharmaceuticals Inc. net income decreased from 2021 to 2022 and from 2022 to 2023.
Comprehensive income Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Exclude changes in equity resulting from investments by owners and distributions to owners. Regeneron Pharmaceuticals Inc. comprehensive income decreased from 2021 to 2022 and from 2022 to 2023.